Proteomics in diabetic nephropathy

Proteomics - Clinical Applications

Volumn 2, Issue 3, 2008, Pages 301-311

  Kim, Hyun Jung ^a   Yoo, Hyun Syuk ^a   Kim, Chan Wha ^a  

^a Korea University   (South Korea)

Author keywords

2 D PAGE; Biomarker; Protein marker discovery

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; ALPHA1 GLYCOPROTEIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CANDESARTAN; CREATININE; GLUTATHIONE PEROXIDASE; HEMOPEXIN; IMMUNOGLOBULIN G; OROSOMUCOID; PIGMENT EPITHELIUM DERIVED FACTOR; RETINOL BINDING PROTEIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; ZINC ALPHA2 GLYCOPROTEIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE COURSE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROALBUMINURIA; MICROCHIP ANALYSIS; MICROFLUIDIC ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN URINE LEVEL; PROTEINURIA; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS; WESTERN BLOTTING;

EID: 41149088788     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780062     Document Type: Review

References (106)

1. Steel, L. F., Haab, B. B., Hanash, S. M., Methods of comparative proteomic profiling for disease diagnostics, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 815, 275-284.
2. O'Farrell, P. H., High resolution two-dimensional electrophoresis of proteins, J. Biol. Chem. 1975, 250, 4007-4021.
3. Görg, A., Obermaier, C., Boguth, G., Harder. A. et al., The current state of two-dimensional electrophoresis with immobilized pH gradients, Electrophoresis 2000, 21, 1037-1053.
4. Karas, M., Hillenkamp, F., Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons, Anal. Chem. 1998, 60, 2299-2301.
5. Fenn, J. B., Mann, M., Meng, C. K., Fenn, J. B. et al., Electrospray ionization for mass spectrometry of large biomolecules, Science 1989, 246, 65-71.
6. Loboda, A. V., Krutchinsky, A. N., Bromirski, M., Ens, W., Standing, K. G., A tandem quadrupole/time-of-flight mass spectrometer with a matrix-assisted laser desorption/ionization source: design and performance, Rapid. Commun. Mass Spectrom. 2000, 14, 1047-1057.
7. Baldwin, M. A., Medzihradszky, K. F., Lock, C. M., Fisher, B. et al., Matrix-assisted laser desorption/ionization coupled with quadrupole/ orthogonal acceleration time-of-flight mass spectrometry for protein discovery, identification, and structural analysis, Anal. Chem. 2001, 73, 1707-1720.
8. Muller, G. A., Muller, C. A., Dihazi, H., Clinical proteomics-on the long way from bench to bedside? Nephrol. Dial. Transplant. 2007, 22, 1297-1300.
9. Petricoin, E. F., Liotta, L. A., Clinical proteomics: application at the bedside, Contrib. Nephrol. 2004, 141, 93-103.
10. Yung, S., Lee, C. Y., Zhang, Q., Lau, S. K. et al., Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways, Nephrol. Dial. Transplant. 2006, 21, 1504-1513.
11. Decramer, S., Wittke, S., Mischak, H., Zurbig, P. et al., Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis, Nat. Med. 2006, 12, 398-400.
12. Dihazi, H., Clinical proteomics: an insight into the urinary proteome. Expert Rev. Proteomics 2006, 3, 481-482.
13. Knepper, M. A., Proteomics and the kidney, J. Am. Soc. Nephrol. 2002, 13, 1398-1408.
14. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., Liotta, L. A., Clinical proteomics: translating benchside promise into bedside reality, Nat. Rev. Drug. Discov. 2002, 1, 683-695.
15. Schaub, S., Rush, D., Wilkins, J., Gibson, I. W. et al., Proteomic-based detection of urine proteins associated with acute renal allograft rejection, J. Am. Soc. Nephrol. 2004, 15, 219-227.
16. O'Riordan, E., Orlova, T. N., Mei, J. J., Butt, K. et al., Bioinformatic analysis of the urine proteome of acute allograft rejection, J. Am. Soc. Nephrol. 2004, 15, 3240-3248.
17. Mauer, S. M., Steffes, M. W., Ellis, E. N., Sutherland, D. E. et al., Structural-functional relationships in diabetic nephropathy, J. Clin. Invest. 1984, 74, 1143-1155.
18. Mogensen, C. E., Christensen, C. K., Vittinghus, E., The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy, Diabetes 1983, 32, 64-78.
19. Mogensen, C. E., Microalbuminuria as a predictor of clinical diabetic nephropathy, Kidney Int. 1987, 31, 673-689.
20. Osterby, R., Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention, Diabetologia 1992, 35, 803-819.
21. Osterby, R., Gall, M. A., Schmitz, A., Nielsen, F. S. et al., Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients, Diabetologia 1993, 36, 1064-1070.
22. Nerlich, A., Schleicher, E. D., Wiest, I., Specks, U., Timpl, R., Immunohistochemical localization of collagen VI in diabetic glomeruli, Kidney Int. 1994, 45, 1648-1656.
23. Kim, Y., Kleppel, M., Butkowski, R., Mauer, M. et al., Differential expression of basement membrane collagen chains in diabetic nephropathy, Am. J. Pathol. 1991, 138, 413-420.
24. Nerlich, A., Schleicher, E., Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions, Am. J. Pathol. 1991, 139, 889-899.
25. Bohle, A., Wehrmann, M., Bogenschutz, O., Batz, C. et al., The pathogenesis of chronic renal failure in diabetic nephropathy, Pathol. Res. Pract. 1991, 187, 251-259.
26. Ceol, M., Nerlich, A., Baggio, B., Anglani, F. et al., Increased glomerular α1 (IV) collagen expression and deposition in long-term diabetic rats in prevented by chronic glycosaminoglycan treatment, Lab. Invest. 1996, 74, 484-495.
27. Schleicher, E. D., Wagner, E. M., Olgemoller, B., Nerlich, A. G., Gerbitz, K. D., Characterization and localization of basement membrane associated heparan sulfate proteoglycan in human tissues, Lab. Invest. 1989, 61, 323-332.
28. Ayo, S. H., Radnik, R. A., Glass, W. F. 2nd, Garoni, J. A. et al., Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium, Am. J. Physiol. 1990, 260, F185-F191.
29. Schleicher, E., Nerlich, A., The role of hyperglycemia in the development of diabetic complications, Horm. Metab. Res. 1996, 28, 367-373.
30. Brownlee, M., Cerami, A., Vlassara, H., Advanced glucosylation end products in tissue and the biochemical basis of diabetic complications, N. Engl. J. Med. 1988, 318, 1315-1321.
31. Mitsuhashi, T., Nakayama, H., Ithoh, T. et al., Immunohistochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat, Diabetes 1993, 42, 826-832.
32. Wolf, G., Ritz, E., Diabetic nephropathy in type 2 diabetes prevention and patient management. J. Am. Soc. Nephrol. 2003, 14, 1396-1405.
33. Bennett, P. H., Haffner, S., Kasiske, B. L., Keane, W. F. et al., Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation, Am. J. Kidney. Dis. 1995, 25, 107-112.
34. Parving, H. H., Lehnert, H., Brochner-Mortensen, J., Gomis, R. et al., The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N. Engl. J. Med. 2001, 345, 870-878.
35. Mogensen, C. E., Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes, N. Engl. J. Med. 1984, 310, 356-360.
36. Nelson, R. G., Knowler, W. C., Pettitt, D. J., Saad, M. F. et al., Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens, Arch. Intern. Med. 1991, 151, 1761-1765.
37. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F. et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N. Engl. J. Med. 2001, 345, 861-869.
38. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T. et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N. Engl. J. Med. 2001, 345, 851-860.
39. Nelson, R. G., Newman, J. M., Knowler, W. C., Sievers, M. L. et al., Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians, Diabetologia 1988, 31, 730-756.
40. Eurich, D. T., Majumdar, S. R., Tsuyuki, R. T., Johnson, J. A., Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes, Diabetes Care 2004, 27, 1330-1334.
41. Parving, H. H., Mauer, M., Ritz, E., Diabetic nephropathy. In: Brenner, B. M. (Ed.), The kidney. Saunders, Philadelphia, PA 2004, pp1777-1818.
42. Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W. et al., Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int. 2003, 63, 225-232.
43. Dinneen, S. F., Gerstein, H. C., The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature, Arch. Intern. Med. 1997, 157, 1413-1418.
44. Gerstein, H. C., Mann, J. F., Yi, Q., Zinman, B. et al., Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, J. Am. Med. Assoc. 2001, 286, 421-426.
45. Garg, J. P., Bakris, G. L., Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease, Vasc. Med. 2002, 7, 35-43.
46. Klose, J., Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues, Humangenetik 1975, 26, 231-243.
47. Anderson, N. G., Anderson, N. L., Tollaksen, S. L., Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis, Clin. Chem. 1979, 25, 1199-1210.
48. Spahr, C. S., Davis, M. T., McGinley, M. D., Robinson, J. H. et al., Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest, Proteomics 2001, 1, 93-107.
49. Thongboonkerd, V., McLeish, K. R., Arthur, J. M., Klein, J. B., Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation, Kidney Int. 2002, 62, 1461-1469
50. Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J. et al., Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots, Proteomics 2004, 4, 1159-1174.
51. Davis, M. T., Spahr, C. S., McGinley, M. D., Robinson, J. H. et al., Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. II. Limitations of complex mixture analyses, Proteomics 2001, 1, 108-117.
52. Thongboonkerd, V., Klein, J. B., Arthur, J. M., Proteomic identification of a large complement of rat urinary proteins, Nephron. Exp. Nephrol. 2003, 95, e69-e78.
53. Thongboonkerd, V., Klein, J. B., Pierce, W. M., Jevans, A. W., Arthur, J. M., Sodium loading changes urinary protein excretion: a proteomic analysis, Am. J. Physiol. Renal. Physiol. 2003, 284, F1155-F1163.
54. Thongboonkerd, V., Barati, M. T., McLeish, K. R., Benarafa, C. et al., Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis, J. Am. Soc. Nephrol. 2004, 15, 650-662.
55. Oh, J., Pyo, J. H., Jo, E. H., Hwang, S. I. et al., Establishment of a near-standard two-dimensional human urine proteomic map, Proteomics 2004, 4, 3485-3497.
56. Sun, W., Li, F., Wu, S., Wang, X. et al., Human urine proteome analysis by three separation approaches, Proteomics 2005, 5, 4994-5001.
57. Castagna, A., Cecconi, D., Sennels, L., Rappsilber, J. et al., Exploring the hidden human urinary proteome via ligand library beads, J. Proteome Res.2005, 4, 1917-1930,
58. Adachi, J., Kumar, C., Zhang, Y., Olsen, J. V., Mann, M., The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins, Genome Biol. 2006, 7, R80.
59. Lafitte, D., Dussol, B., Andersen, S., Vazi, A. et al., Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples, Clin. Biochem. 2002, 35, 581-589.
60. Mischak, H., Kaiser, T., Walden, M., Hillmann, M. et al., Proteomic analysis for the assessment of diabetic renal damage in humans, Clin. Sci. 2004, 107, 485-495.
61. Meier, M., Kaiser, T., Herrmann, A., Knueppel, S. et al., Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis, J. Diabetes Complications 2005, 19, 223-232.
62. Rossing, K., Mischak, H., Parving, H. H., Christensen, P. K. et al., Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns, Kidney Int. 2005, 68, 193-205.
63. Thongboonkerd, V., Songtawee, N., Sritippayawan, S., Urinary proteome profiling using microfluidic technology on a chip, J. Proteome Res. 2007, 6, 2011-2018.
64. Wright, G. L. Jr., SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis, Expert. Rev. Mol. Diagn. 2002, 2, 549-563.
65. Fung, E., Diamond, D., Simonsesn, A. H., Weinberger, S. R., The use of SELDI ProteinChip array technology in renal disease research, Methods Mol. Med. 2003, 86, 295-312.
66. Tang, N., Tornatore, P., Weinberger, S. R., Current developments in SELDI affinity technology, Mass Spectrom. Rev. 2004, 23, 34-44.
67. Seibert, V., Wiesner, A., Buschmann, T., Meuer, J., Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research, Pathol. Res. Pract. 2004, 200, 83-94.
68. Out, H. H., Can, H., Spentzos, D., Nelson, R. G. et al., Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy, Diabetes Care. 2007, 30, 638-643.
69. Zhang, R., Barker, L., Pinchev, D., Marshall, J. et al., Mining biomarkers in human sera using proteomic tools, Proteomics 2004, 4, 244-256.
70. Sundsten, T., Eberhardson, M., Goransson, M., Bergsten, P., The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes, Proteome Sci. 2006, 4, 22.
71. Cho, E. H., Kim, M. R., Kim, H. J., Lee, D. Y. et al., The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis, Proteomics Clin. Appl. 2007, 1, 362-372.
72. Kim, H. J., Cho, E. H., Yoo, J. H., Kim, P. K. et al., Proteome analysis of serum from type 2 diabetics with nephropathy, J. Proteome Res. 2007, 6, 735-743.
73. Argiles, A., Mourad, G., Mion, C., Atkins, R. C., Haiech, J., Two-dimensional gel electrophoresis of urinary proteins in kidney diseases, Contrib. Nephrol. 1990, 83, 1-8.
74. Thongboonkerd, V., Klein, J. B., Jevans, A. W., McLeish, K. R., in: Thongboonkerd, V., Klein, J. B. (Eds.), Proteomics in Nephrology, Karger, Basel, Switzerland 2004, pp. 292-307.
75. Thongboonkerd, V., Malasit, P., Renal and urinary proteomics: current applications and challenges, Proteomics 2005, 5, 1033-1042.
76. Thongboonkerd, V., Gozal, E., Sachleben, L. R., Arthur, J. M. et al., Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension, J. Biol. Chem. 2002, 277, 34708-34716.
77. Wolf, W. C., Yoshida, H., Agata, J., Chao, L. et al., Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure, Kidney Int. 2000, 58, 730-739.
78. Katori, M., Majima, M., Hayashi, I., Fujita, T. et al., Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension, Biol. Chem. 2001, 382, 61-64.
79. Jain, S., Rajput, A., Kumar, Y., Uppuluri, N. et al., Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder, J. Assoc. Physicians India. 2005, 53, 513-520.
80. Sharma, K., Lee, S., Han, S., Lee, S. et al., Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy, Proteomics 2005, 5, 2648-2655.
81. Rao, P. V., Lu, X., Standley, M., Pattee, P. et al., Proteomic identification of urinary biomarkers of diabetic nephropathy, Diabetes Care 2007, 30, 629-637.
82. Shoshan, S. H., Admon, A., Proteomics in clinical laboratory diagnosis, Adv. Clin. Chem. 2005, 39, 159-184.
83. Joo, W. A., Lee, D. Y., Kim, C. W., Development of an effective sample preparation method for the proteome analysis of body fluids using 2-D gel electrophoresis, Biosc. Biotechnol. Biochem. 2003, 67, 1574-1577.
84. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects, Mol. Cell. Proteomics 2002, 1, 845-867.
85. Thadikkaran, L., Siegenthaler, M. A., Crettaz, D., Queloz, P. A. et. al., Proteomics 2005, 5, 3019-3034.
86. Nykjaer, A., Dragun, D., Walther, D., Vorum, H. et al., An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3, Cell 1999, 96, 507-515.
87. Malecki, M. T., Klupa, T., Wanic, K., Cyganek, K. et al., Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population, Diabetes Res. Clin. Pract. 2002, 57, 99-104.
88. Avissar, N., Ornt, D. B., Yagil, Y., Horowitz, S. et al., Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am. J. Physiol. 1994, 266, C367-C375.
89. Chu, F. F., Esworthy, R. S., Doroshow, J. H., Doan, K., Liu, X. F., Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents, Blood 1992, 79, 3233-3238.
90. Ozden, M., Maral, H., Akaydin, D., Cetinalp, P., Kalender, B., Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients, Clin. Biochem. 2002, 35, 269-273.
91. Mimic-Oka, J., Simic, T., Djukanovic, L., Reljic, Z., Davicevic, Z., Alteration in plasma antioxidant capacity in various degrees of chronic renal failure, Clin. Nephrol. 1999, 51, 233-241.
92. Ceballos-Picot, I., Witko-Sarsat, V., Merad-Boudia, M., Nguyen, A. T. et al., Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure, Free Radic. Biol. Med. 1996, 21, 845-853.
93. Sommerburg, O., Grune, T., Ehrich, J. H., Siems, W. G., Adaptation of glutathion-peroxidase activity to oxidative stress occurs in children but not in adult patients with end-stage renal failure undergoing hemodialysis, Clin. Nephrol. 2002, 58, S31-S36.
94. Joss, N., Jardine, A., Gaffney, D., Boulton-Jones, J. M., Influence of apolipoprotein E genotype on progression of diabetic nephropathy, Nephron. Exp. Nephrol. 2005, 101, e127-133.
95. Chen, G., Paka, L., Kako, Y., Singhal, P. et al., A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion, J. Biol. Chem. 2001, 276, 49142-29147.
96. Bruschi, M., Catarsi, P., Candiano, G., Rastaldi, M. P. et al., Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, Kidney Int. 2003, 63, 686-695.
97. Bristow, C. L., Di Meo, F., Arnold, R. R., Specific activity of alpha1proteinase inhibitor and alpha2macroglobulin in human serum: application to insulin-dependent diabetes mellitus, Clin. Immunol. Immunopathol. 1998, 89, 247-259.
98. Murakami, T., Komiyama, Y., Egawa, H., Murata, K., Elevation of factor Xla-alpha 1-antitrypsin complex levels in NIDDM patients with diabetic nephropathy, Diabetes 1993, 42, 233-238.
99. Talmud, P. J., Martin, S., Steiner, G., Flavell, D. M. et al., Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene, Arterioscler. Thromb. Vasc. Biol. 2003, 23, 644-649.
100. Poland, D. C., Garcia, Vallejo, J. J., Niessen, H. W., Nijmeyer, R. et al., Activated human PMN synthesize and release a strongly fucosylated glycoform of alpha1-acid glycoprotein, which is transiently deposited in human myocardial infarction, J. Leukoc. Biol. 2005, 78, 453-461.
101. Timmins, G. S., Davies, M. J., Song, D. X., Muller-Eberhard, U., EPR studies on the effects of complexation of heme by hemopexin upon its reactions with organic peroxides, Free Radic. Res. 1995, 23, 559-569.
102. Thompson, A., Danesh, J., Associations between apolipoprotein B, apolipoprotein Al, the apolipoprotein B/Al ratio and coronary heart disease: a literature-based meta-analysis of prospective studies, J. Intern. Med. 2006, 259, 481-492.
103. Davis, P. H., Dawson, J. D., Riley, W. A., Lauer, R. M., Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study, Circulation 2001,w 104, 2815-2819.
104. Onat, A., Hergenc, G., Sansoy, V., Fobker, M. et al., Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders, Atherosclerosis 2003, 168, 81-89.
105. Sherif, K., Kushner, H., Falkner, B. E., Sex hormone-binding globulin and insulin resistance in African-American women, Metabolism 1998, 47, 70-74.
106. Brscic, E., Bergerone, S., Gagnor, A., Colajanni, E. et al., Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up, Am. Heart J. 2000, 139, 979-784.